Insider Selling: Liquidia Co. (NASDAQ:LQDA) Insider Sells 2,445 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,445 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Rajeev Saggar also recently made the following trade(s):

• On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22.

Liquidia Price Performance

NASDAQ LQDA opened at $14.40 on Friday. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.99. The stock has a market capitalization of $1.22 billion, a P/E ratio of -8.83 and a beta of 0.23. The firm’s 50-day moving average is $11.47 and its two-hundred day moving average is $11.06.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LQDA shares. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Scotiabank started coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Liquidia currently has a consensus rating of “Buy” and a consensus price target of $25.38.

Hedge Funds Weigh In On Liquidia

Several large investors have recently made changes to their positions in the stock. Signaturefd LLC raised its position in Liquidia by 38,400.0% in the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after purchasing an additional 9,984 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in shares of Liquidia in the third quarter valued at $100,000. Ballentine Partners LLC purchased a new stake in shares of Liquidia in the 3rd quarter valued at $110,000. Whitcomb & Hess Inc. lifted its stake in Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after acquiring an additional 1,074 shares in the last quarter. Finally, Walleye Trading LLC boosted its holdings in Liquidia by 54.7% during the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after acquiring an additional 4,670 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).